4.6 Review

Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies

Journal

LANCET DIABETES & ENDOCRINOLOGY
Volume 6, Issue 5, Pages 404-415

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30401-1

Keywords

-

Funding

  1. Novartis
  2. Ipsen
  3. Roche

Ask authors/readers for more resources

In this Review, we discuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We describe advances in genetics, blood-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and molecularly targeted therapy, and the potential role of immunotherapy in the treatment of NETs. Suggested treatment algorithms for NETs of ileal or jejunal origin and of pancreatic origin are presented.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available